KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Other Working Capital Changes (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Other Working Capital Changes for 13 consecutive years, with -$1.5 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Other Working Capital Changes rose 30.88% year-over-year to -$1.5 million, compared with a TTM value of -$2.8 million through Dec 2025, down 188.97%, and an annual FY2025 reading of -$2.8 million, down 188.97% over the prior year.
  • Other Working Capital Changes was -$1.5 million for Q2 2025 at Travere Therapeutics, down from -$1.3 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $38.9 million in Q3 2021 and bottomed at -$38.7 million in Q4 2021.
  • Average Other Working Capital Changes over 5 years is -$1.6 million, with a median of -$1.5 million recorded in 2024.
  • The sharpest move saw Other Working Capital Changes surged 1652.19% in 2021, then plummeted 493.21% in 2023.
  • Year by year, Other Working Capital Changes stood at -$38.7 million in 2021, then skyrocketed by 89.59% to -$4.0 million in 2022, then crashed by 38.4% to -$5.6 million in 2023, then surged by 68.83% to -$1.7 million in 2024, then grew by 15.7% to -$1.5 million in 2025.
  • Business Quant data shows Other Working Capital Changes for TVTX at -$1.5 million in Q2 2025, -$1.3 million in Q1 2025, and -$1.7 million in Q4 2024.